The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Sweis, Randy
overview Dr. Sweis is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immunotherapies. His laboratory research is focused on modulating the tumor microenvironment to facilitate anti-tumor immune responses, using mouse models of bladder and skin cancers. In the clinic, he uses his expertise in developmental therapeutics and clinical pharmacology to investigate biomarkers and novel therapeutic strategies to improve immunotherapy efficacy in patients.
One or more keywords matched the following items that are connected to Sweis, Randy
Item TypeName
Concept Immunotherapy
Academic Article Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Academic Article Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Academic Article T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Academic Article Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
Academic Article Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Academic Article Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.
Grant Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
Academic Article Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Academic Article FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.
Academic Article Germline genetic contribution to the immune landscape of cancer.
Academic Article The Tumor Microenvironment of Bladder Cancer.
Academic Article Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
Academic Article A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer.
Academic Article The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Academic Article Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms.
Academic Article Melanoma and microbiota: Current understanding and future directions.
Search Criteria
  • Immunotherapy